Fatal veno-occlusive disease of the liver following high dose chemotherapy, irradiation and bone marrow transplantation

The American Journal of Medicine
W G WoodsJ H Kersey

Abstract

In two patients fatal veno-occlusive disease of the liver developed after bone marrow transplantation for underlying malignancies. Both had received significant pretransplant chemotherapy, including cystosine arabinoside, and total body irradiation. The diagnosis of veno-occlusive disease should be considered in patients in whom hepatomegaly, ascites and deteriorating liver function tests develop after they have received cancer chemotherapy.

References

Sep 28, 1977·Virchows Archiv. A, Pathological Anatomy and Histology·A Burkhardt, G Klöppel
Apr 24, 1975·The New England Journal of Medicine·E D ThomasC D Buckner
Nov 1, 1976·Annals of Internal Medicine·P F GrinerC H Packman
Feb 1, 1976·The Journal of Pediatrics·C Mellis, P M Bale
Sep 1, 1974·The British Journal of Radiology·R A NebesarR M Filler
Oct 1, 1957·Archives of Disease in Childhood·D B JELLIFFEK L MUKHERJEE
Mar 1, 1960·The American Journal of Medicine·D L WEISS, R DE LOS SANTOS

❮ Previous
Next ❯

Citations

Jan 1, 1982·Virchows Archiv. A, Pathological Anatomy and Histology·H WeitzM Eder
Jul 1, 1993·Indian Journal of Pediatrics·T S Vats
Jun 1, 1989·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·J M CossetJ Dutreix
Dec 16, 1993·The New England Journal of Medicine·W M Lee
Dec 1, 1987·Acta Pathologica Japonica·M ShiraiW Mori
Apr 1, 1989·Annals of the Rheumatic Diseases·D E LemleyD J Nashel
Jun 1, 1982·Gut·M J FarthingT J McElwain
Aug 31, 2010·Paediatric Drugs·Maria Giuseppina CefaloRiccardo Riccardi
Aug 1, 1996·Hematology/oncology Clinics of North America·A Y Su, P Loeb
May 6, 2015·Journal of Clinical and Experimental Hepatology·Sahaj Rathi, Radha K Dhiman
Mar 11, 2015·Journal of Clinical and Experimental Hepatology·Cathy Q Fan, James M Crawford
Oct 30, 2016·Seminars in Diagnostic Pathology·Milton J Finegold
Aug 1, 1987·Australian and New Zealand Journal of Medicine·P S Craft, R G Pembrey
Jan 1, 1984·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·G B McDonaldE D Thomas
Feb 14, 2006·Seminars in Oncology·Nasir ShahabDonald C Doll
Feb 14, 2006·Seminars in Oncology·Justin FloydMichael C Perry
Sep 27, 2008·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·John Coutsouvelis, Carmela E Corallo
Apr 5, 2008·Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis·Edward PeresEsteban Abella
Oct 1, 1981·Australian and New Zealand Journal of Medicine·R RowlandG Ward
Jul 12, 2018·Neurospine·Vishnu Senthil, Satish Balaji
Apr 18, 2001·The Oncologist·P D King, M C Perry
Aug 9, 2003·Expert Opinion on Drug Safety·Bradley SachsMichael C Perry
May 20, 2014·Liver International : Official Journal of the International Association for the Study of the Liver·Nerea Fernandez-RosBruno Sangro

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.